Please use this identifier to cite or link to this item:
|Title:||Estimating the lifetime economic burden of Parkinson's disease in Singapore|
|Keywords:||Cost of illness|
|Source:||Zhao, Y.J.,Tan, L.C.S.,Au, W.L.,Heng, D.M.K.,Soh, I.A.L.,Li, S.C.,Luo, N.,Wee, H.L. (2013-02). Estimating the lifetime economic burden of Parkinson's disease in Singapore. European Journal of Neurology 20 (2) : 368-374. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1468-1331.2012.03868.x|
|Abstract:||Background and purpose: We aimed to estimate the lifetime cost of Parkinson's disease (PD) from the societal perspective. Methods: A convenience sample of English or Chinese-speaking patients with PD was recruited from a PD and Movement Disorders Centre in Singapore to complete a financial burden questionnaire. Sociodemographic and clinical data were retrieved from hospital databases. Markov cohort model analysis was performed (cycle length, 1-year; duration, death or reached 100 years old). Patients were assumed to progress from one Markov state to the next state or death without skipping states or regressing. All model parameters were based on published local data. Results: In 195 patients with PD (median age: 68.9, male: 51.8%), the simulated lifetime cost of PD was Singapore Dollar (SGD) 60 487 (EUR purchasing power parity 56 253) per patient. Direct medical, non-medical and indirect cost accounted for 18.8%, 12.8% and 68.4% of total lifetime cost, respectively. The top three components of total lifetime cost were productivity losses (67.6%), pharmacotherapy (11.4%) and home care (8.7%). One-way sensitivity analysis and probabilistic sensitivity analyses revealed that estimates were sensitive to cost at H&Y stage 1, 2 and 2.5 and productivity losses. Conclusions: The lifetime cost of PD is evaluated for the first time. This cost is substantial and comparable to the lifetime cost of intracerebral haemorrhage in at least one study. Our study identified several priority areas for research and policy formulation: reducing productivity losses, reducing cost of pharmacotherapy, avoiding hospitalization and reducing home care cost. © 2012 The Author(s) European Journal of Neurology © 2012 EFNS.|
|Source Title:||European Journal of Neurology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 4, 2017
checked on Dec 7, 2017
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.